Companies · Biotechnology

Genesis New Ventures, LLC

MISSOULA · Biotechnology

Diligence memoA one-page analyst read on Genesis New Ventures, LLC — recommendation, valuation, rhythm, risks.
$650K
Total raised · real
2
Rounds
5.5×
Latest step-up
Top 88%
Sector rank · raised
Pre-Seed
Latest stage · inferred · Fri Mar 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Genesis New Ventures, LLC looks over-valued against its niche peers and is active on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Over-valued
  • Modeled value is 1.73× the median modeled value of Pre-Seed Biotechnology companies in 2025–2027 (79 peers) — value vs value, same stage and era.
Active
  • Last raise 16 mo ago; this sector typically re-raises about every 14 months.
  • Raising on or ahead of the sector's normal rhythm.

Procedural diagnosis est. — rule-based common-sense checks over the filing pattern, issuer name, activity cadence, and surfaced operating evidence.

Issuer-vehicle patternmedium confidence

Genesis New Ventures, LLC behaves more like a recurring private-offering issuer than a conventional venture-backed operating company.

Issuer structure
Company-like
No recurring-offering pattern strong enough to override normal financing interpretation.
Lifecycle
4.0 yr record
Peak capital year was 2025 with $550K across 1 filings.
Market position
ahead of 13% of Biotechnology peers
Capital scale is ahead of 13% of Biotechnology peers; modeled value is above 4% of peers by modeled value. Large capital with mid-pack modeled value can signal an issuer/program profile rather than operating-company growth.
Valuation reliability
Normal applicability
Stage/dilution valuation models are weakest when the issuer is broad-sector, recurring, or vehicle-like.
Operating evidence
Sparse
No clear CEO/founder/principal role is surfaced, so operating-company confidence is lower.
Data quality
Consistent
Canonical totals and visible filing detail are broadly aligned.
What triggered this
  • Legal name looks like an issuer vehicle rather than a product company.
  • No clearly named CEO/founder/principal role in the public records surfaced here.
  • No verified homepage on the profile yet.
  • Capital program peaked in 2025: $550K across 1 filings.
  • Largest single filing was $550K on 2025-03-07.
How to read the page
  • Read this less like a startup funding journey and more like a capital-raising program.
  • Stage-based valuation and peer labels have lower applicability for this pattern.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

Genesis New Ventures, LLC is one of 4293 Biotechnology companies tracked from MISSOULA. By capital raised it ranks in the long tail (ahead of 13% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
$1M–$5M
Issuer revenue
Rule 506(b)
Reg D exemption
3
Investors (latest)
2022
Year incorporated
2025-03-07
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$500K$1.0M$1.5M$2.0MPre-Seed · 2022-06-27 Raised $100K (real) Modeled valuation $1.6M (est)$100K$1.6MPre-Seed2022Pre-Seed · 2025-03-07 Raised $550K (real) Modeled valuation $1.7M (est)$550K$1.7MPre-Seed2025+$550KCumulative $650K

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Pre-Seed$100K · 2022
Pre-Seed extension$550K · 2025

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$1.7M
Base estimate est.
$293K
Conservative case
$4.6M
Upside case
$3.1M
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Pre-Seeda round under $1.0M). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Pre-Seed · modeled $1.6M · 2022-06-272022Pre-Seed · modeled $1.7M · 2025-03-072025
Model inputs · modeled:benchmark-stage-stepup-v1
18%
Dilution assumption
Implied ownership sold in the financing.
24%
Survival probability
10% low · 44% high
1.86×/yr
Annual markup
2.52×/yr upside case
1.3 yr
Elapsed time used
1.3 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
32 mo
Avg between rounds
$241K/yr
Capital velocity
4.0 yr
On record since
2022
First round
2
Rounds on file
How it compares to the market

Benchmarked against 4293 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 0.1× of median
This company$650K
Sector median$7.2M
Latest round — vs other Pre-Seed rounds in sector (real $, this stage) 1.3× above median
This company$550K
Sector median$412K
Modeled value — vs sector median (estimate, all stages) 0.0× of median
This company$1.7M
Sector median$64.2M

Raised more than 13% of sector peers (real $). Modeled value above 4% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Pre-Seed) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #16 of 79.

This companyCohort peer
$1.0M$10.0M$100K$1.0M$10.0MCapital raised (log)Illexcor Holdings, LLC · Pre-Seed Raised $1.0M · modeled $3.0M (est)Reprogram Biosciences, Inc. · Pre-Seed Raised $1.0M · modeled $2.7M (est)Maxymune Therapeutics, Inc. · Pre-Seed Raised $850K · modeled $2.7M (est)EnZeta Immunotherapies, Inc. · Pre-Seed Raised $840K · modeled $2.6M (est)Eliaz Therapeutics Inc. · Pre-Seed Raised $850K · modeled $2.5M (est)Mekiri Bio, Inc. · Pre-Seed Raised $1.0M · modeled $2.3M (est)Cellerate Technologies, LLC · Pre-Seed Raised $1.0M · modeled $2.2M (est)Tinos Therapeutics, Inc. · Pre-Seed Raised $1.0M · modeled $2.2M (est)Factor Bioscience LLC · Pre-Seed Raised $1.0M · modeled $2.2M (est)Toby, Inc. · Pre-Seed Raised $1.4M · modeled $2.1M (est)MedVector Corp · Pre-Seed Raised $2.1M · modeled $2.1M (est)Real Health International Wellness Corp. · Pre-Seed Raised $1.0M · modeled $2.0M (est)Genesis New Ventures, LLC (this company) Raised $650K · modeled $1.7M (est)Genesis New Ventures, LLC
CompanyStageRaised · realValue · estvs peer med.
Illexcor Holdings, LLCPre-Seed$1.0M$3.0M3.15×
Reprogram Biosciences, Inc.Pre-Seed$1.0M$2.7M2.83×
Maxymune Therapeutics, Inc.Pre-Seed$850K$2.7M2.79×
EnZeta Immunotherapies, Inc.Pre-Seed$840K$2.6M2.73×
Eliaz Therapeutics Inc.Pre-Seed$850K$2.5M2.59×
Mekiri Bio, Inc.Pre-Seed$1.0M$2.3M2.36×
Cellerate Technologies, LLCPre-Seed$1.0M$2.2M2.34×
Tinos Therapeutics, Inc.Pre-Seed$1.0M$2.2M2.32×
Factor Bioscience LLCPre-Seed$1.0M$2.2M2.28×
Toby, Inc.Pre-Seed$1.4M$2.1M2.23×
MedVector CorpPre-Seed$2.1M$2.1M2.19×
Real Health International Wellness Corp.Pre-Seed$1.0M$2.0M2.11×
Genesis New Ventures, LLC this companyPre-Seed$650K$1.7M1.73×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Pre-Seed$100K2022-06-27$556K$1.6M90%
Pre-Seed$550K2025-03-07$3.1M$1.7M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Pre-Seed$100K2022-06-27
    • First recorded raise — entered as Pre-Seed.
    • 1 investor on this round.
  2. Pre-Seed$550K2025-03-07
    • Raised again after 32 mo — slower than the ~14 mo sector norm.
    • Round 5.5× larger than the prior — scaling up.
    • Revenue band moved $0–$1M → $1M–$5M.
    • 3 investors on this round.
Intelligence
2027 ~Q4
Modeled next raise · ~32mo cadence
$1.6M
Modeled next size est.range $1.1M$2.6M
5.5×
Last step-up
$241K/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Greg Downey6 other2022-06
Donald Running4 other2022-06
Daniel F Justin1 other2025-03
Matt Milanowski1 other2022-06
Connor Sullivan2022-06
Dan Justin2022-06
Justin F Kaler2025-03
Registry & provenance

Genesis New Ventures, LLC is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1937493
SEC CIK
2022
Incorporated
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Genesis Innovation Group, LLCBiotechnologyPre-Seed$500K$5.5Mnetwork1 shared operator · same sector · same stage
Imagine Pharma LlcBiotechnologyPre-Seed$650K$3.5Msame sector · same stage
RetinalGenix Technologies Inc.BiotechnologyPre-Seed$653K$4.0Msame sector · same stage
Modulate Bio Inc.BiotechnologyPre-Seed$660K$3.2Msame sector · same stage
Gateway Biotechnology, Inc.BiotechnologyPre-Seed$633K$1.7Msame sector · same stage
Embold Therapeutics, Inc.BiotechnologyPre-Seed$630K$878Ksame sector · same stage
Gemina Laboratories Ltd.BiotechnologyPre-Seed$673K$1.7Msame sector · same stage
RPT Labworks, Inc.BiotechnologyPre-Seed$690K$1.4Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Genesis Therapeutics, Inc.BiotechnologySeries D+$3.3B90%
Redwood Scientific Technologies, Inc.BiotechnologySeed$10.5M89%
Organogenesis Holdings Inc.BiotechnologySeries D+$1.3B88%
Stemgenics, Inc.BiotechnologySeed$19.8M88%
Newomics Inc.BiotechnologySeed$149.0M87%
Jellatech, Inc.BiotechnologySeed$27.3M87%
Rafael Holdings, Inc.BiotechnologySeries D+$2.9B87%
Generation Bio Co.BiotechnologySeries D+$4.6B87%
Frequently asked
How much funding has Genesis New Ventures, LLC raised?
Genesis New Ventures, LLC has raised approximately $650K in disclosed capital across 2 recorded financing rounds, aggregated from public filings.
What is Genesis New Ventures, LLC's estimated valuation?
Provath's modeled valuation for Genesis New Ventures, LLC is approximately $1.7M (modeled range $293K–$4.6M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is Genesis New Ventures, LLC at?
Genesis New Ventures, LLC's latest modeled financing stage is Pre-Seed. Its most recent recorded round closed around Fri Mar 07.
What does Genesis New Ventures, LLC do and where is it based?
Genesis New Ventures, LLC operates in the Biotechnology sector, based in MISSOULA.
Explore related

See where Genesis New Ventures, LLC sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at Genesis New Ventures, LLC, claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.